Please login to the form below

Not currently logged in
Email:
Password:

talimogene laherparepvec

This page shows the latest talimogene laherparepvec news and features for those working in and with pharma, biotech and healthcare.

Amgen submits melanoma and cholesterol drugs to EMA

Amgen submits melanoma and cholesterol drugs to EMA

Amgen submits melanoma and cholesterol drugs to EMA. Regulator will assess talimogene laherparepvec and evolocumab. ... One of the drugs is talimogene laherparepvec, an oncology treatment that Amgen has submitted for use in the treatment of adults with

Latest news

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hall & Partners

We are a specialist brand and communications research consultancy offering you fresh ideas at every stage of the brand planning...

Latest intelligence

More of the same: The importance of strategic communications planning for biosimilar entry
GCI Health's Hannah Morris considers the importance of strategic communications planning for biosimilar entry, a market anticipated to deliver between €8-26bn in savings across the European Union by 2020....
Online Physician Communities
How can pharma realise the power of digital?
Firstly, by making it owned and driven by the most senior leadership team in the business...
Remapping the market: Does Pharma's global model need a shake up?
For patients, carers and professionals, wherever they are in the world, digital technology is inherent in their everyday lives. Digital is, so to speak, a global language. The success of...